Perspectives in MicroRNA Therapeutics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Perspectives in MicroRNA Therapeutics
The authors provide further insight into microRNA biology, and the simplicity of anti-miR oligonucleotide drug delivery.


Pharmaceutical Technology
Volume 35, pp. a18-s24

Conclusion

Targeting pathways of human disease with microRNA-based drugs represents a novel and potentially powerful therapeutic approach. Recent data demonstrate not only that dysregulated microRNAs are associated with and can cause human disease, but that selective modulation through anti-miR intervention can provide therapeutic benefits. Anti-miR oligonucleotides can be easily administered through local or parenteral injection routes with sufficient uptake of the agent to achieve sustained target inhibition in tissues and organs without the need of formulation. Improvements in anti-miR chemical design and pharmacokinetic properties will allow further exploration of microRNA biology and broaden the utility of microRNA therapeutics.

Kevin Steffy, PhD,* is the global alliance manager, Charles Allerson, PhD, is the associate director of chemistry, and Balkrishen Bhat, PhD, is the senior director of chemistry, all at Regulus Therapeutics, 3545 John Hopkins Ct., San Diego, CA 92121, tel. 858.202.6321,
.

*To whom all correspondence should be addressed.

References

1. S.T. Crooke et al., "Mechanisms of Antisense Drug Action, an Introduction," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 3–47.

2. S.M. Elbashir et al., Nature 411 (6386), 494–498 (2001).

3. A. Jackson and P.S. Linsley, Discovery Medicine 9 (47), 311–318 (2010).

4. J. Krutzfeldt et al., Nature 438 (7068), 685–689 (2005).

5. D.P. Bartel, Cell 116 (2), 281–297 (2004).

6. E.C. Lai, Nat. Rev. Genet 30 (4), 363–364 (2002).

7. T. Thum et al., Nature 456 (7224), 980–984 (2008).

8. L. Ma et al., Nature 28 (4), 341–347 (2010).

9. R.E. Lanford et al., Science 327 (5962), 198–201 (2010).

10. P.P. Seth et al., J. Med. Chem. 52 (1), 10–13 (2009).

11. A.A. Levin, R. Zu, and R.S. Geary, "Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 183–215.

12. B. Monia et al. J. Biol. Chem. 268 (19), 14514–14522 (1993).

13. R.S. Geary, R. Zu, and A.A. Levin, "Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides in Animals and Man," in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp. 306–326.

14. S.C. Semple et al., Nature Biotech. 28 (2), 172–176 (2010).

15. S.V. Dongen et al., Nature Methods 5 (12) 1023–1025 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here